These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 8822957

  • 1. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
    Vallera DA, Panoskaltsis-Mortari A, Jost C, Ramakrishnan S, Eide CR, Kreitman RJ, Nicholls PJ, Pennell C, Blazar BR.
    Blood; 1996 Sep 15; 88(6):2342-53. PubMed ID: 8822957
    [Abstract] [Full Text] [Related]

  • 2. Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin.
    Vallera DA, Panoskaltsis-Mortari A, Blazar BR.
    Protein Eng; 1997 Sep 15; 10(9):1071-6. PubMed ID: 9464572
    [Abstract] [Full Text] [Related]

  • 3. Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells.
    Chan CH, Blazar BR, Greenfield L, Kreitman RJ, Vallera DA.
    Blood; 1996 Aug 15; 88(4):1445-56. PubMed ID: 8695865
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-2 fusion protein with anti-CD3 single-chain Fv (sFv) selectively protects T cells from dexamethasone-induced apoptosis.
    Kim EJ, Cho D, Hwang SY, Kim TS.
    Vaccine; 2001 Nov 12; 20(3-4):608-15. PubMed ID: 11672928
    [Abstract] [Full Text] [Related]

  • 5. Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model.
    Vallera DA, Kuroki DW, Panoskaltsis-Mortari A, Buchsbaum DJ, Rogers BE, Blazar BR.
    Blood; 2000 Aug 01; 96(3):1157-65. PubMed ID: 10910937
    [Abstract] [Full Text] [Related]

  • 6. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA, Carroll SF, Snover DC, Carlson GJ, Blazar BR.
    Blood; 1991 Jan 01; 77(1):182-94. PubMed ID: 1984794
    [Abstract] [Full Text] [Related]

  • 7. Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin.
    Ma S, Hu H, Thompson J, Stavrou S, Scharff J, Neville DM.
    Bioconjug Chem; 1997 Jan 01; 8(5):695-701. PubMed ID: 9327133
    [Abstract] [Full Text] [Related]

  • 8. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion.
    Thompson J, Stavrou S, Weetall M, Hexham JM, Digan ME, Wang Z, Woo JH, Yu Y, Mathias A, Liu YY, Ma S, Gordienko I, Lake P, Neville DM.
    Protein Eng; 2001 Dec 01; 14(12):1035-41. PubMed ID: 11809934
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.
    Wang Z, Duran-Struuck R, Crepeau R, Matar A, Hanekamp I, Srinivasan S, Neville DM, Sachs DH, Huang CA.
    Bioconjug Chem; 2011 Oct 19; 22(10):2014-20. PubMed ID: 21866954
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient.
    Mysliwietz J, Thierfelder S.
    Blood; 1992 Nov 15; 80(10):2661-7. PubMed ID: 1358260
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.